NOVN.VX - Novartis AG

Swiss - Swiss Delayed Price. Currency in CHF
87.90
+0.24 (+0.27%)
As of 3:19PM CET. Market open.
Stock chart is not supported by your current browser
Previous Close87.66
Open88.88
Bid87.86 x 373700
Ask87.88 x 1281100
Day's Range87.76 - 89.34
52 Week Range72.96 - 89.34
Volume2,445,579
Avg. Volume3,278,602
Market Cap224.199B
Beta (3Y Monthly)N/A
PE Ratio (TTM)25.77
EPS (TTM)N/A
Earnings DateJan 23, 2018 - Jan 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.59
  • The Wall Street Journal2 hours ago

    [$$] Novartis CEO Bets on Cutting-Edge Science to Remake Drug Giant

    AG’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs. The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumors for close-range radiotherapy. ’s ambition to get ahead on innovative therapies that he believes will drive significant future growth.

  • Reuters3 days ago

    Novartis' blood disorder drug gets FDA approval for expanded use

    Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder. The drug, Promacta, received the green light as a combination with standard immunosuppressive therapy to treat patients two years and older suffering from treatment-resistant severe aplastic anemia (SAA). SAA is a blood disorder in which a patient's bone marrow fails to produce enough red blood cells, white blood cells and platelets.

  • Reuters3 days ago

    Alphabet unit halts glucose-detecting contact lens project

    Alphabet Inc's life sciences division Verily said on Friday that it was putting on hold one of its oldest and highest-profile projects, a smart contact lens designed to help monitor sugar levels. The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears. In a blog update, Verily cited https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.

  • Reuters4 days ago

    Novartis launches third-to-market Remicade copy in Germany

    Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. Novartis's Sandoz generics unit in May won European approval for Zessly, known generically as infliximab.

  • The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

  • Reuters4 days ago

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis (NOVN.S) is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters. Earlier, Swiss newspaper Tages-Anzeiger reported the Basel-based drugmaker was preparing to split off Sandoz, citing an employee representative as well as participants in a Novartis investor event last week in London.

  • Reuters4 days ago

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters.

  • Reuters4 days ago

    Novartis says 'completely committed' to Sandoz, not planning split-off

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan ...

  • Reuters11 days ago

    Novartis division Sandoz recalls one lot of blood pressure drug

    Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

  • Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
    Motley Fool11 days ago

    Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending September 30, 2018.

  • Here's Why PTC Therapeutics Dropped 18% in October
    Motley Fool11 days ago

    Here's Why PTC Therapeutics Dropped 18% in October

    The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.

  • Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript
    Motley Fool13 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending September 30, 2018.

  • Reuters17 days ago

    Novartis abandons effort for U.S. approval of biosimilar rituximab

    Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. The decision comes after the U.S. Food and Drug Administration (FDA) sought additional information to support the company's application for the drug, which is approved already in the EU, Switzerland, Japan and Australia, the company said in a statement. "We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine," said Stefan Hendriks, global head of biopharmaceuticals at Sandoz.

  • Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
    Zacks17 days ago

    Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

    Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

  • GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript
    Motley Fool19 days ago

    GlaxoSmithKline plc (GSK) Q3 Earnings Conference Call Transcript

    GSK earnings call for the period ending September 30, 2018.

  • Big Pharma's Price Freezes Aren't Fooling Anybody
    Bloomberg19 days ago

    Big Pharma's Price Freezes Aren't Fooling Anybody

    Novartis, Merck, and Amgen all beat analysts’ third-quarter earnings expectations and raised either their sales or EPS guidance for the full year (Amgen raised both). Roche doesn't report EPS on a quarterly basis, but beat sales expectations on the back of strong U.S. results. Pfizer’s earnings were messier, but its price rollback wasn’t to blame for its woes.

  • Reuters19 days ago

    FDA approves Novartis' copy of AbbVie bestseller Humira

    The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday. Although approved, Novartis' Sandoz unit can only begin U.S. sales of Humira's biosimilar in 2023, according to a licensing agreement sealed with AbbVie this month. The biosimilar, Hyrimoz, is approved https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf for treating several diseases, including rheumatoid arthritis, the FDA said.

  • Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
    Zacks19 days ago

    Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line

    Glaxo beat earnings estimates while sales were in-line in the third quarter of 2018.

  • Novartis May Beat Ironwood Pharmaceuticals to the Punch
    Motley Fool20 days ago

    Novartis May Beat Ironwood Pharmaceuticals to the Punch

    Novartis may be on track to win FDA approval of a sickle disease drug before Ironwood.

  • Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript
    Motley Fool20 days ago

    Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript

    INCY earnings call for the period ending September 30, 2018.

  • Reuters21 days ago

    Drugmakers tout new medicines as eye disease battle intensifies

    Switzerland's Roche and Novartis and other drugmakers are touting new treatments for a blindness-causing disease that hits millions of older people, as patent expiries are set to open up one of medicine's most lucrative markets. Roche's experimental treatment faricimab showed long-lasting effectiveness against age-related macular degeneration (AMD), the Basel-based drugmaker said on Monday, potentially reducing the frequency of uncomfortable, direct-in-the-eye shots. For years, Lucentis, from Roche and Novartis, and Bayer and Regeneron's Eylea, have dominated AMD treatment, with combined 2017 sales topping $9 billion.

  • Reuters21 days ago

    Novartis, Pfizer join forces on potentially lucrative fatty liver disease

    ZURICH/NEW YORK (Reuters) - Novartis AG (NOVN.S) and Pfizer Inc (PFE.N) are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. The Swiss and U.S. drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH.

  • Reuters21 days ago

    Novartis, Pfizer join forces on potentially lucrative fatty liver disease

    ZURICH/NEW YORK, Oct 29 (Reuters) - Novartis AG and Pfizer Inc are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. The Swiss and U.S. drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH.

  • This Big Pharma Bet Isn't Paying Off Yet -- and It's Costing You
    Motley Fool22 days ago

    This Big Pharma Bet Isn't Paying Off Yet -- and It's Costing You

    Who's paying the price tag for big pharma's big bet, which hasn't delivered impressive returns? Look in the mirror.

  • Benzinga24 days ago

    The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 26) Endocyte, Inc. (NASDAQ: ECYT ) Imprimis Pharmaceuticals ...